A phase I microplaque study of XCUR17 in patients with mild to moderate psoriasis

Trial Profile

A phase I microplaque study of XCUR17 in patients with mild to moderate psoriasis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 May 2018

At a glance

  • Drugs XCUR 17 (Primary)
  • Indications Psoriasis
  • Focus Adverse reactions
  • Most Recent Events

    • 15 May 2018 According to an Exicure media release, company began dosing patients in early April 2018 and trial data is expected during the third quarter of this year.
    • 15 May 2018 Status changed from planning to recruiting, according to an Exicure media release.
    • 15 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top